Biological
Idecabtagene vicleucel clinical trials
Also written bb2121 and ide-cel.
- studies test it
- 8
- open now
- 0
- in phase 3
- 2
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 3
Celgene (5) · Memorial Sloan Kettering Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1)
Often tested with
Tested in the same studies.
Fludarabine (2) · Cyclophosphamide (2) · Lenalidomide (2) · Tisagenlecleucel (1) · Axicabtagene ciloleucel (1) · Brexucabtagene autoleucel (1) · Lisocabtagene maraleucel (1) · Daratumumab (1)
Studies
Open first, then newest update. How each study uses idecabtagene vicleucel is read from its arms, and is right about nine times in ten.
Testing it · 8
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 3CelgeneNCT03651128Written as bb2121
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedPhase 2Medical College of WisconsinNCT05032820Written as bb2121
- A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05393804Written as Ide-cel (bb2121)
- A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationActive, not recruitingPhase 3CelgeneNCT06045806Written as idecabtagene vicleucel
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as Abecma, Intravenous Suspension
- Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedPhase 2CelgeneNCT03361748Written as bb2121
- A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedPhase 1CelgeneNCT04196491Written as bb2121
- Study of bb2121 in Multiple MyelomaCompletedPhase 1CelgeneNCT02658929Written as bb2121
Given in every arm · 2 — idecabtagene vicleucel is usual care beside what is tested
- Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedPhase 1CelgeneNCT04855136Written as BB2121
- An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedPhase 2CelgeneNCT03601078Written as bb2121
Codes
What other systems call idecabtagene vicleucel · ClinicalTrials.gg INT001587
- MeSH (NLM) C000715380idecabtagene vicleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8PX1X7UG4DIDECABTAGENE VICLEUCELConfirmed FDA, NLM
- RxNorm 2536430One source FDA
- NCI Thesaurus C117729Idecabtagene VicleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000715380 | idecabtagene vicleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8PX1X7UG4D | IDECABTAGENE VICLEUCEL | Confirmed FDA, NLM |
| RxNorm | 2536430 | — | One source FDA |
| NCI Thesaurus | C117729 | Idecabtagene Vicleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.